Meteorin-like protein/METRNL/Interleukin-41 ameliorates atopic dermatitis-like inflammation.

METRNL can bind to KIT receptor and subsequently alleviate the allergic inflammation of AD by inhibiting the expansion of immune cells, and downregulating inflammatory gene expression by regulating the level of active WNT pathway molecule β-Catenin.